News | PET Imaging | May 25, 2016

Chinese Study Shows PET Testing Combo Enhances Lung Lesion Evaluation

Combining computed bioconductance with PET imaging improves ability to distinguish malignant from benign lesions

China, computed bioconductance, CB, PET, positron emission tomography, lung lesions

May 25, 2016 — Positron emission tomography (PET) is used commonly in the diagnosis of suspected lung cancer. Computed bioconductance (CB) id being investigated as a non-invasive way to predict whether an suspicious abnormality in the lung is benign or malignant. In a new study, researchers found that CB combined with PET before biopsy of suspicious lesions could improve diagnostic effectiveness of potentially cancerous lesions detected by computed tomography (CT) scan.

In this prospective analysis, researchers found CB results combined with PET improved the ability to distinguish malignant from benign conditions compared with PET alone.

"In China, lung cancer is the leading cause of cancer mortality and causes huge health burdens and expense. Adding CB measurement to standard PET scanning could prove to be a useful, non-invasive diagnostic tool for aiding diagnosis of patients with lung cancer" said Dawei Yang, M.D., lead author, Zhongshan Hospital Fudan University in Shanghai, China.

Study results were shared at the Chinese Thoracic Society (CHEST) World Congress 2016, April 15-17 in Shanghai.

For more information:

Related Content

Philips Launches IntelliSpace Discovery Research Platform at RSNA
Technology | Artificial Intelligence | November 20, 2018
Ahead of the 2018 Radiological Society of North America Annual Meeting (RSNA), Nov. 25-30 in Chicago, Royal Philips...
Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Life Image and Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...